Lung fibrosis-immunodeficiency-46,XX gonadal dysgenesis syndrome

Lung fibrosis-immunodeficiency-46,XX gonadal dysgenesis syndrome is an extremely rare multisystem disorder characterized by the combination of three major features: interstitial lung disease progressing to pulmonary fibrosis, primary immunodeficiency, and 46,XX gonadal dysgenesis (also known as pure gonadal dysgenesis in individuals with a 46,XX karyotype). Affected individuals, who are phenotypically female, present with streak gonads leading to absent or incomplete puberty, primary amenorrhea, and infertility due to nonfunctional ovaries. The immunodeficiency component involves defects in cellular and/or humoral immunity, predisposing patients to recurrent and severe infections. Progressive pulmonary fibrosis leads to worsening respiratory function and is a major cause of morbidity and mortality. The syndrome affects the reproductive system (gonadal dysgenesis with absent secondary sexual characteristics), the immune system (increased susceptibility to infections), and the respiratory system (progressive lung fibrosis). Onset of symptoms typically occurs during childhood or adolescence, when the immunodeficiency and pulmonary manifestations become clinically apparent, and gonadal dysgenesis is recognized at the expected time of puberty. Treatment is largely supportive and symptom-directed, including hormone replacement therapy for gonadal dysgenesis, immunoglobulin replacement or antimicrobial prophylaxis for immunodeficiency, and management of pulmonary fibrosis with anti-fibrotic agents or supportive respiratory care. Lung transplantation may be considered in severe cases. No curative therapy is currently available, and prognosis depends largely on the severity and progression of the pulmonary and immunological components.

Common questions about Lung fibrosis-immunodeficiency-46,XX gonadal dysgenesis syndrome